Amgen, Inc. et al. v. Sanofi et al.
Infringement action filed 18 Nov 2021 in the U.S. Supreme Court and closed 18 May 2023, with 7 patents asserted. Recorded basis of termination: appeal dismissed.
Case record
- Case no.
- 21-757
- Verdict cause
- Infringement action
- Court
- U.S. Supreme Court
- Court level
- Supreme Court
- Case region
- District of Columbia
- Chief judge
- Neil M. Gorsuch
- Trial level
- Judicial review
- Filed – Closed
- 18 Nov 2021 – 18 May 2023
- Duration
- 546 days
- Basis of termination
- Appeal Dismissed
- Products & marks
- Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) · Hierarchical load estimation system, method and program
Check this patent against your own product
Prior art, claim scope, infringement exposure and design-around routes. Every answer cites the records behind it.
Get an FTO claim chart- 01Ranked prior artEvery hit source-linked
- 02Claim-level comparisonAgainst your own product
- 03Legal statusAcross 174 jurisdictions
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
- Legal status
- Active
- Granted
- 28 Oct 2014
- Earliest priority
- 23 Aug 2007
- Est. expiry
- 22 Aug 2028
- Validity challenges
- None recorded
- Licences recorded
- None recorded
- Inventors
- JACKSON, SIMON MARK · WALKER, NIGEL PELHAM CLINTON · PIPER, DEREK EVAN · SHEN, WENYAN · KING, CHADWICK TERENCE · KETCHEM, RANDAL ROBERT · MEHLIN, CHRISTOPHER · CARABEO, TERESA ARAZAS
- Classification
- C07K16/40C07K16/00C12N15/113
- Prosecution counsel
- Knobbe, Martens, Olson & Bear, LLP
- Examiner
- WEN, SHARON
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
- Legal status
- Active
- Granted
- 18 Nov 2014
- Earliest priority
- 4 Aug 2008
- Est. expiry
- 22 Aug 2028
- Validity challenges
- None recorded
- Licences recorded
- None recorded
- Inventors
- JACKSON, SIMON MARK · WALKER, NIGEL PELHAM CLINTON · PIPER, DEREK EVAN · SHEN, WENYAN · KING, CHADWICK TERENCE · KETCHEM, RANDAL ROBERT · MEHLIN, CHRISTOPHER · CARABEO, TERESA ARAZAS
- Classification
- C07K16/40C07K16/00
- Prosecution counsel
- Knobbe, Martens, Olson & Bear, LLP
- Examiner
- WEN, SHARON
Also asserted in this case
5 moreThe docket lists 7 asserted patents. Full bibliographic detail, drawings and prosecution history for the remaining 5 asserted patents are one query away in Eureka.
- US8829165B2Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
- US8871913B2Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
- US8583698B2Hierarchical load estimation system, method and program
- US8859741B2Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
- US8883983B2Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
Parties of record
Amgen, Inc.
- Core tech
- C07K16/40C07K16/00C12N15/113
- Counsel
- Jeffrey Alan Lamken
- Firm
- MoloLamken LLP
- Also named
- Amgen USA, Inc. · Amgen Manufacturing Limited
Sanofi
- Core tech
- Not recorded
- Counsel
- Paul D. Clement.
- Firm
- Clement & Murphy, PLLC
- Also named
- Regeneron Pharmaceuticals, Inc. · Sanofi-Aventis U.S., LLC · Aventisub, LLC
Counsel of record
| Attorney | For | Role |
|---|---|---|
| Jeffrey Alan Lamken | Amgen, Inc. | Plaintiff |
| Paul D. Clement. | Sanofi | Defendant |
Basis of termination
From the record · verbatim“Section 112 of the Patent Act reflects Congress’s judgment that if an inventor claims a lot, but enables only a little, the public does not receive its benefit of the bargain. For more than 150 years, this Court has enforced the statutory enablement requirement according to its terms. If the Court had not done so in Incandescent Lamp, it might have been writing decisions like Holland Furniture in the dark. Today’s case may involve a new technology, but the legal principle is the same. The judgment is Affirmed.”
Case 21-757 · U.S. Supreme Court · closed 18 May 2023
Related cases
Three questions this record usually leads to. Each one runs against the full litigation and patent corpus, and cites what it finds.
Frequently asked questions
What is case 21-757?
21-757 is a patent infringement action brought by Amgen, Inc. against Sanofi, filed on 18 Nov 2021 in the U.S. Supreme Court. The case closed on 18 May 2023.
Which patents were asserted in 21-757?
US8871914B2 (“Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)”), assigned to AMGEN INC., currently active; US8889834B2 (“Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)”), assigned to AMGEN INC., currently active; US8829165B2 (“Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)”), assigned to AMGEN INC.; US8871913B2 (“Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)”), assigned to AMGEN INC.; US8583698B2 (“Hierarchical load estimation system, method and program”), assigned to NEC CORPORATION; US8859741B2 (“Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)”), assigned to AMGEN INC.; US8883983B2 (“Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)”), assigned to AMGEN INC.. The record also lists Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) and Hierarchical load estimation system, method and program.
How was case 21-757 terminated?
The recorded basis of termination is appeal dismissed. The termination text reads: “Section 112 of the Patent Act reflects Congress’s judgment that if an inventor claims a lot, but enables only a little, the public does not receive its benefit of the bargain. For more than 150 years, this Court has enforced the statutory enablement requirement according to its terms. If the Court had not done so in Incandescent Lamp, it might have been writing decisions like Holland Furniture in the dark. Today’s case may involve a new technology, but the legal principle is the same. The judgment is Affirmed.”
How long did case 21-757 take?
546 calendar days, from filing on 18 Nov 2021 to closure on 18 May 2023.
Who were the attorneys and the judge in 21-757?
Chief Judge Neil M. Gorsuch presided. Jeffrey Alan Lamken is recorded as counsel for plaintiff Amgen. Paul D. Clement. appears for defendant Sanofi.
Disclaimer. This page reproduces publicly available court docket data for case 21-757 and is provided for general information and reference only. It is not legal advice and must not be relied upon as such.
Docket data has limits. Records are drawn from a snapshot and may lag the live docket. Sealed filings, amended complaints, counterclaims and post-closure motions may not be reflected. Party names, attorney names and firm affiliations are reproduced as recorded and may contain omissions. Where a field is absent from the record, this page marks it as not recorded rather than inferring a value.
No characterisation of the parties or the outcome. This page reports what the record contains. Nothing here should be read as an assertion that any party infringed, that any patent is valid or invalid, that any settlement occurred, or that any party prevailed.
No FTO or validity opinion. Nothing on this page constitutes a freedom-to-operate, novelty, validity or infringement opinion. Any decision touching a live patent dispute should be verified independently and reviewed with qualified patent counsel.